CMS has introduced the MAHA ELEVATE model to expand lifestyle medicine in Medicare, a move experts support but say will hinge on effective implementation. The post What Health Experts Are Saying About the MAHA ELEVATE Program appeared first on MedCity News.
Alveus Therapeutics’ Phase 2-ready lead drug hits the same two targets as Amgen’s MariTide, but with the potential for a dosing advantage. The startup’s pipeline also includes molecules that could compete with drugs in development by Roche and Novo Nordisk. The post Startup Alveus Therapeutics Emerges With $160M to Shape the Future of Obesity Drugs…
Passage of the bill in the Senate remains uncertain
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Goal is to prepare University of California health centers for success in value-based care models by participating in alternative payment model contracts
Health system working with startup Atalan on development of a platform module designed to bridge clinician retention and patient experience data
British health standards exec succeeds Charles Jaffe, M.D., Ph.D., who led HL7 for nearly two decades
OpenAI says that with the additional context, ChatGPT Health could help users understand the tradeoffs of different insurance options based on their healthcare patterns
Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity. The post Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition appeared first…
In his latest JAMA Forum column, KFF’s Larry Levitt explores how unaffordable health care is in the U.S. in the context of the debate over extending enhanced Affordable Care Act premium tax credits and an upcoming election where affordability will likely be front and center.